HIV-1 latency reversal and immune enhancing activity of IL-15 is not influenced by sex hormones

被引:0
|
作者
Holmberg, Carissa S. [1 ]
Levinger, Callie [1 ]
Abongwa, Marie [1 ]
Ceriani, Cristina [2 ,3 ]
Archin, Nancie M. [2 ,3 ]
Siegel, Marc [4 ]
Ghosh, Mimi [5 ]
Bosque, Alberto [1 ]
机构
[1] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA
[2] Univ N Carolina, UNC HIV Cure Ctr, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[4] George Washington Sch Med & Hlth Sci, Washington, DC USA
[5] George Washington Univ, Dept Epidemiol, Washington, DC 20037 USA
关键词
ESTROGEN-RECEPTORS; T-CELLS; TESTOSTERONE LEVELS; PROGESTERONE; ESTRADIOL; INTERLEUKIN-15; INFLAMMATION; ACTIVATION; INFECTION; RESERVOIR;
D O I
10.1172/jci.insight.180609
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The role of different biological variables including biological sex, age, and sex hormones in Human immunodeficiency virus (HIV) cure approaches is not well understood. The gamma c-cytokine IL-15 is a clinically relevant cytokine that promotes immune activation and mediates HIV reactivation from latency. In this work, we examined the interplay that biological sex, age, and sex hormones 17(3-estradiol, progesterone, and testosterone may have on the biological activity of IL-15. We found that IL-15-mediated CD4+T + T cell activation was higher in female donors than in male donors. This difference was abrogated at high 17(3-estradiol concentration. Additionally, there was a positive correlation between age and both IL-15-mediated CD8+ + T cell activation and IFN-gamma production. In a primary cell model of latency, biological sex, age, or sex hormones did not influence the ability of IL-15 to reactivate latent HIV. Finally, 17(3-estradiol did not consistently affect reactivation of translation-competent reservoirs in CD4+ + T cells from people living with HIV who are antiretroviral therapy (ART) suppressed. Our study has found that biological sex and age, but not sex hormones, may influence some of the biological activities of IL-15. Understanding how different biological variables may affect HIV cure therapies will help us evaluate current and future clinical trials aimed toward HIV cure in diverse populations.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Reversal of Latency as Part of a Cure for HIV-1
    Rasmussen, Thomas Aagaard
    Tolstrup, Martin
    Sogaard, Ole Schmeltz
    TRENDS IN MICROBIOLOGY, 2016, 24 (02) : 90 - 97
  • [2] Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation
    Swaminathan, Sanjay
    Qiu, Ju
    Rupert, Adam W.
    Hu, Zonghui
    Higgins, Jeanette
    Dewar, Robin L.
    Stevens, Randy
    Rehm, Catherine A.
    Metcalf, Julia A.
    Sherman, Brad T.
    Baseler, Michael W.
    Lane, H. Clifford
    Imamichi, Tomozumi
    PLOS ONE, 2016, 11 (11):
  • [3] IL-15 reprogramming compensates for NK cell mitochondrial dysfunction in HIV-1 infection
    Moreno-Cubero, Elia
    Alrubayyi, Aljawharah
    Balint, Stefan
    Ogbe, Ane
    Gill, Upkar S.
    Matthews, Rebecca
    Kinloch, Sabine
    Burns, Fiona
    Rowland-Jones, Sarah L.
    Borrow, Persephone
    Schurich, Anna
    Dustin, Michael
    Peppa, Dimitra
    JCI INSIGHT, 2024, 9 (04)
  • [4] Novel Latency Reversal Agents for HIV-1 Cure
    Spivak, Adam M.
    Planelles, Vicente
    ANNUAL REVIEW OF MEDICINE, VOL 69, 2018, 69 : 421 - 436
  • [5] Latency reversal and viral clearance to cure HIV-1
    Margolis, David M.
    Garcia, J. Victor
    Hazuda, Daria J.
    Haynes, Barton F.
    SCIENCE, 2016, 353 (6297) : 362 - +
  • [6] Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal
    Cisneros, William J.
    Soliman, Shimaa H. A.
    Walter, Miriam
    Simons, Lacy M.
    Cornish, Daphne
    De Fabritiis, Simone
    Halle, Ariel W.
    Kim, Eun-Young
    Wolinsky, Steven M.
    Lorenzo-Redondo, Ramon
    Shilatifard, Ali
    Hultquist, Judd F.
    PLOS PATHOGENS, 2024, 20 (09)
  • [7] Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults
    Kalams, Spyros A.
    Parker, Scott
    Jin, Xia
    Elizaga, Marnie
    Metch, Barbara
    Wang, Maggie
    Hural, John
    Lubeck, Michael
    Eldridge, John
    Cardinali, Massimo
    Blattner, William A.
    Sobieszczyk, Magda
    Suriyanon, Vinai
    Kalichman, Artur
    Weiner, David B.
    Baden, Lindsey R.
    PLOS ONE, 2012, 7 (01):
  • [8] Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1
    Kristoff, Jan
    Palma, Mariana L.
    Garcia-Bates, Tatiana M.
    Shen, Chengli
    Sluis-Cremer, Nicolas
    Gupta, Phalguni
    Rinaldo, Charles R.
    Mailliard, Robbie B.
    EBIOMEDICINE, 2019, 43 : 295 - 306
  • [9] Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
    Vollbrecht, Thomas
    Angerstein, Aaron O.
    Menke, Bryson
    Kumar, Nikesh M.
    de Oliveira, Michelli Faria
    Richman, Douglas D.
    Guatelli, John C.
    RETROVIROLOGY, 2020, 17 (01)
  • [10] HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal
    Wu, Guoxin
    Swanson, Michael
    Talla, Aarthi
    Graham, Donald
    Strizki, Julie
    Gorman, Daniel
    Barnard, Richard J. O.
    Blair, Wade
    Sogaard, Ole S.
    Tolstrup, Martin
    Ostergaard, Lars
    Rasmussen, Thomas A.
    Sekaly, Rafick-Pierre
    Archin, Nancie M.
    Margolis, David M.
    Hazuda, Daria J.
    Howell, Bonnie J.
    JCI INSIGHT, 2017, 2 (16)